

Treatment for metastatic hormone-sensitive prostate cancer

Live from the studio: Plenary session 05

Sunday 11 July
11:45 - 13:15

Location Virtual room 1

Chairs
A. Briganti, Milan (IT)
K. Fizazi, Villejuif (FR)
S. Gillessen Sommer, Bellinzona (CH)
A. Villers, Lille (FR)

Learning objectives

Metastatic hormone-sensitive prostate cancer can be approached with a variety of treatment options. This session examines the options for treatment of both de-novo and recurrent mHSPCa. Case discussion place the lessons in a "daily practice" scenario, so that participants see the practical implications of their choice of treatment.

11:45 - 11:53	State-of-the-art lecture De novo versus recurrent metastatic mHSPC: What is the role of modern imaging? D. Murphy, Melbourne (AU)
11:53 - 12:36	Treatment options for de-novo mHSPCa
11:53 - 12:01	Systemic treatments: How to choose the right treatment for the right patient N.W. Clarke, Manchester (GB)
12:01 - 12:06	Local treatment: Radiation therapy (primary +/- lymph nodes) P. Ost, Ghent (BE)
12:06 - 12:11	Local treatment: Surgery (primary +/- lymph nodes) A. Briganti, Milan (IT)
12:11 - 12:19	Future: Personalised medicine for mHSPCa? K. Fizazi, Villejuif (FR)
12:19 - 12:36	Case discussion Patient with high volume disease <i>Case presenter</i> M. Heck, Munich (DE) <i>Panel</i> N.W. Clarke, Manchester (GB) A. Briganti, Milan (IT) K. Fizazi, Villejuif (FR) P. Ost, Ghent (BE)
12:36 - 13:10	Treatment options for recurrent mHSPCa
12:36 - 12:44	Systemic treatments: When and how? C. Sweeney, Boston (US)
12:44 - 12:49	The role of imaging-guided treatments: Radiotherapy P. Blanchard, Villejuif (FR)
12:49 - 12:54	The role of imaging-guided treatments: Surgery T. Maurer, Hamburg (DE)
12:54 - 13:10	Case discussion Patient with oligometastatic disease <i>Case presenter</i> R.C.N. Van Den Bergh, Nieuwegein (NL) <i>Panel</i> P. Blanchard, Villejuif (FR) T. Maurer, Hamburg (DE) C. Sweeney, Boston (US)
13:10 - 13:15	Closing remarks